Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Strand Therapeutics is a clinical-stage biopharmaceutical company at the forefront of developing next-generation mRNA therapeutics. They are pioneering programmable, self-replicating mRNA technology designed to create long-acting immunotherapies. Their initial focus is on oncology, aiming to deliver precisely targeted treatments that can overcome the limitations of current therapies. By engineering mRNA to sense and respond to disease biomarkers, Strand aims to improve efficacy and reduce side effects, ultimately transforming the treatment landscape for cancer and potentially other diseases. Their lead candidate, STX-001, is the first programmable, self-replicating mRNA therapy being evaluated for solid tumors.
The Cambridge headquarters serves as the primary center for Strand Therapeutics' research and development, laboratory operations, corporate administration, and strategic leadership in advancing its novel mRNA platform.
The facility is equipped with state-of-the-art BSL-2 laboratory spaces essential for advanced mRNA research, synthesis, and preclinical development. It also features collaborative office environments designed to foster scientific innovation and teamwork.
Strand Therapeutics cultivates a dynamic, innovative, and science-driven work culture. There is a strong emphasis on collaboration, cutting-edge research, and a collective mission to translate scientific breakthroughs into impactful patient therapies in a fast-paced biotech environment.
Its Cambridge location is highly significant, placing Strand Therapeutics within one of the world's leading biotechnology ecosystems. This provides unparalleled access to top-tier talent, renowned research institutions, potential collaborators, and venture capital.
Strand Therapeutics' primary operations are currently concentrated in the United States at its Cambridge, MA headquarters. As a clinical-stage company, its global activities may include international clinical trial sites and research collaborations. Future global presence will likely expand with the clinical and commercial development of its mRNA therapeutic pipeline, potentially through strategic partnerships for market access in different regions.
60 Tufts Street
Cambridge
MA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Strand Therapeutics' leadership includes:
Strand Therapeutics has been backed by several prominent investors over the years, including:
Over the past 12 months, Strand Therapeutics has made significant additions to its executive leadership team, appointing a new Chief Operating Officer and a Chief Development Officer. These hires signal the company's focus on scaling operations and advancing its clinical pipeline. No major executive departures have been publicly announced during this period.
Discover the tools Strand Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Strand Therapeutics likely utilizes common corporate email address formats. Based on industry standards and company naming conventions, the most probable format is [first_initial][last]@[domain] or [first].[last]@[domain]. The company's domain is strandtx.com.
[first_initial][last]@strandtx.com
Format
jbecraft@strandtx.com
Example
85%
Success rate
GlobeNewswire • March 21, 2024
Strand Therapeutics announced the appointment of Robert Mabry, Ph.D., as its Chief Development Officer. Dr. Mabry will oversee the company's preclinical and clinical development strategies for its pipeline of programmable mRNA therapeutics....more
GlobeNewswire • January 9, 2024
Strand Therapeutics appointed Christopher K. Lee, MBA, as its Chief Operating Officer. Mr. Lee will be responsible for leading the company's operational functions, including manufacturing, supply chain, quality, and program management....more
GlobeNewswire • September 7, 2023
Strand Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for STX-001. This marks the first IND clearance for a programmable, self-replicating mRNA therapy designed for the treatment of solid tumors....more
GlobeNewswire • May 10, 2023
Strand Therapeutics appointed Yasir Al-Wakeel, BM BCh, as its Chief Medical Officer. Dr. Al-Wakeel will lead the clinical development strategy and operations for Strand's pipeline of next-generation mRNA therapeutics....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Strand Therapeutics, are just a search away.